Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:AEZS - Post by User

Comment by Tencentson Jun 25, 2024 1:39pm
97 Views
Post# 36105382

RE:Merger closed, proposed name announced, AGM in 21 days...

RE:Merger closed, proposed name announced, AGM in 21 days...I would expect the following to happen at the agm<br /> 1. approval of name<br /> 2. approval of merger<br /> 3.appointment of auditors&nbsp;<br /> 4. approval of board&nbsp;<br /> 5.approval of financial statements 2023&nbsp;<br /> <br /> operational business matters are unlikely to be considered<br /> these are for the executive management team to deal with&nbsp;<br /> <br /> <br />
<< Previous
Bullboard Posts
Next >>